Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DexCom, Inc.
  6. News
  7. Summary
    DXCM   US2521311074

DEXCOM, INC.

(DXCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

DEXCOM INC : Other Events, Financial Statements and Exhibits (form 8-K)

11/22/2021 | 05:05pm EST

ITEM 8.01 OTHER EVENTS.

On November 22, 2021, DexCom, Inc. ("DexCom") filed an automatic shelf Registration Statement on Form S-3 (File No. 333-261265) with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), which automatically became effective upon filing (the "Registration Statement"), a prospectus dated November 22, 2021 included therein (the "Base Prospectus") and a final prospectus supplement, filed with the Commission pursuant to Rule 424(b) under the Securities Act (the "Prospectus Supplement" and together with the Base Prospectus, the "Prospectus") to register 2,025,036 shares of DexCom's common stock, par value $0.001 per share (the "Shares"), to be issued pursuant to that certain Amended and Restated Collaboration and License Agreement, dated as of November 20, 2018, by and among DexCom, Verily Life Sciences LLC (an Alphabet Company) and Verily Ireland Limited (the "Collaboration and License Agreement") and that certain Common Stock Purchase Agreement, dated as of November 20, 2018, by and among DexCom, Verily Life Sciences LLC and Onduo, LLC, a joint venture partially owned by Verily (the "Purchase Agreement" and together with the Collaboration and License Agreement, the "Agreements"). The Shares were previously registered pursuant to an automatic shelf Registration Statement on Form S-3 (File No. 333-228495) filed by DexCom with the Commission on November 20, 2018 under the Securities Act, which automatically became effective upon filing (the "Prior Registration Statement"), a prospectus dated November 20, 2018 included therein (the "Prior Base Prospectus") and a final prospectus supplement dated November 20, 2018, filed with the Commission pursuant to Rule 424(b) under the Securities Act (the "Prior Prospectus Supplement" and together with the Prior Base Prospectus, the "Prior Prospectus"). The Prior Registration Statement expired on or about November 20, 2021.

A copy of the Purchase Agreement was previously filed by DexCom on a Current Report on Form 8-K filed with the Commission on November 20, 2018 and a copy of the Collaboration and License Agreement was filed by DexCom on its annual report on Form 10-K for the year ending December 31, 2018 filed with the Commission on February 21, 2019. A copy of the opinion of Fenwick & West LLP, relating to the validity of the Shares to be issued pursuant to the Agreements and Prospectus, is filed with this Current Report on Form 8-K as Exhibit 5.1.

Item 9.01 Financial Statements and Exhibits



(d) Exhibits



Exhibit
  No.        Description

5.1            Opinion of Fenwick & West LLP

104          Cover Page Interactive Data File (embedded within the Inline XBRL Document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about DEXCOM, INC.
01/19DexCom Shares Rise After Wells Fargo Upgrade
MT
01/19Raymond James Adjusts DexCom's Price Target to $538 from $618, Keeps Outperform Rating
MT
01/19Wells Fargo Upgrades DexCom to Overweight From Equalweight; Price Target is $575
MT
01/11UBS Adjusts DexCom Price Target to $640 From $660, Maintains Buy Rating
MT
01/10Health Care Stocks Slip Premarket Monday
MT
01/10DexCom Issues Q4, Full Year 2021 Revenue Guidance
MT
01/10DEXCOM : Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary Da..
PU
01/10DEXCOM INC : Results of Operations and Financial Condition, Other Events, Financial Statem..
AQ
01/10Dexcom, Inc. Reports Preliminary Unaudited Revenue Guidance for the Fourth Quarter and ..
CI
01/10Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary D..
BU
More news
Analyst Recommendations on DEXCOM, INC.
More recommendations